Nid yw'n briodol defnyddio'r broses IPFR yn rheolaidd i benderfynu a ddylid cael mynediad at feddyginiaethau amddifad a thra amddifad - mae'r meddyginiaethau hynny wedi'u datblygu'n benodol i drin cyflyrau meddygol prin iawn.
It is not appropriate to routinely use the IPFR process to determine access to orphan or ultra-orphan medicines – those medicines developed specifically to treat very rare medical conditions.